Mach7 Technologies released a first quarter cashflow report which highlighted some lumpiness in cash receipts and that synergy targets are on track following the Client Outlook acquisition, explains Morgans.

During the quarter nine new customers were added and three contract renewals were signed which shows the broker strong support for the product offering.

The Add rating and target price of $1.49 are maintained. 

Sector: Health Care Equipment & Services.

Target price is $1.49.Current Price is $0.93. Difference: $0.56 - (brackets indicate current price is over target). If M7T meets the Morgans target it will return approximately 38% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2020 Acquisdata Pty Ltd., source FN Arena